"By analysing multi-omics data, CardiaTec's platform investigates relationships that stretch across every level of biology to shed light on how cardiovascular diseases develop."
"This approach enables the discovery of novel drug targets with well-defined mechanisms of action, increasing the likelihood of successful preclinical and subsequent clinical translation," Raphael Peralta, the company's co-founder and CEO, told TNW.
"CardiaTec is also building the first and largest human heart tissue multi-omics dataset. To do this, it has established a network of 65 hospitals across the UK and the US."
"With the fresh round, the company plans to expand its platform and move proprietary drug targets towards the preclinical stage."
Collection
[
|
...
]